Proprietary bacTrl™ Gene therapy platform

Our unique technology harnesses a genetically modified bacterial vector encoding a plasmid to safely and selectively deliver oral DNA vaccines and therapies directly to targeted tissues.

Living Bio-factories


Symvivo has invented and patented a novel protein based mechanism that enables the bacteria to consistently produce and deliver therapeutic plasmid DNA to colonized tissues.

Extending to new opportunities

Through oral vaccination or intravenous infusion, our bacTRL Gene Therapy Platform™ can be applied to the development of therapies across a range of indications, including cancer, cardiovascular injuries and infectious and genetic diseases.

Living Bio-factories
Get in touch

get in touch

Symvivo values working with life sciences partners worldwide. To learn more about why Symvivo is your partner of choice, please contact our Business Development team.